Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the STANDARD study

Abstract Background Apixaban, a non‐vitamin K oral anticoagulant (NOAC), was approved in Japan in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial fibrillation (NVAF). However, the safety and effectiveness of apixaban in clinical practice have not yet been elucida...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hiroshi Inoue, Michiaki Umeyama, Takako Yamada, Hiroyuki Hashimoto, Akira Komoto, Masahiro Yasaka
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2019-06-01
coleção:	Journal of Arrhythmia
Assuntos:	apixaban atrial fibrillation postmarketing surveillance safety
Acesso em linha:	https://doi.org/10.1002/joa3.12184
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!